SKIL:NYSESkillsoft Corp. Analysis
Data as of 2026-05-01 - not real-time
$7.72
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Skillsoft Corp. (SKIL) is trading at $7.72, well below its DCF‑derived fair value of $30.15, implying a substantial upside potential on a purely valuation basis. The stock sits just under its 20‑day SMA of $5.96 and 50‑day SMA of $4.88, but remains far beneath the 200‑day SMA of $10.03, indicating a neutral long‑term trend. Technical momentum is mixed: the RSI sits at 67.4, edging into overbought territory, while the MACD line ($0.70) sits above its signal ($0.57), generating a bullish signal. Volume has been decreasing, and the market cap of only $68 million combined with a 30‑day volatility of 112% underscores a fragile liquidity profile. Recent earnings showed a modest revenue dip of 2.3% YoY to $130.7 million and a surprise‑negative EPS, yet the forward EPS estimate of $4.64 yields a forward PE of 1.66, highlighting a potential earnings rebound. The company’s balance sheet is strained, with $587 million of debt against $101 million of cash and a negative book value per share of $‑3.44, amplifying the risk of continued losses.
The news flow emphasizes a strategic pivot toward the Percipio platform and an upgrade to a Zacks Rank 2 Buy, suggesting that analysts see a turnaround in earnings estimates. However, the stock’s max drawdown of –84% and negative profit margins signal that any recovery will require disciplined execution. Given the high beta of 1.79, the stock is likely to amplify market moves, and the current resistance at $7.74 provides a short‑term ceiling. Investors should weigh the deep discount to intrinsic value against the substantial operational and financial headwinds before deciding on exposure.
The news flow emphasizes a strategic pivot toward the Percipio platform and an upgrade to a Zacks Rank 2 Buy, suggesting that analysts see a turnaround in earnings estimates. However, the stock’s max drawdown of –84% and negative profit margins signal that any recovery will require disciplined execution. Given the high beta of 1.79, the stock is likely to amplify market moves, and the current resistance at $7.74 provides a short‑term ceiling. Investors should weigh the deep discount to intrinsic value against the substantial operational and financial headwinds before deciding on exposure.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 5/10
Key Factors
- RSI approaching overbought levels
- Price near immediate resistance at $7.74
- Decreasing volume and high short‑term volatility
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant discount to DCF fair value
- Bullish MACD crossover
- Strategic focus on Percipio platform and analyst upgrade
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Potential earnings upside reflected in forward PE of 1.66
- Low price‑to‑sales multiple (0.13)
- Undervalued status despite high debt, offering upside if turnaround succeeds
Key Metrics & Analysis
Financial Health
Revenue Growth-2.30%
Profit Margin-27.27%
P/E Ratio1.7
ROE-439.57%
ROA-2.36%
P/B Ratio-2.2
Op. Cash Flow$25.1M
Free Cash Flow$56.6M
Technical Analysis
TrendNeutral
RSI67.4
Support$3.72
Resistance$7.74
MA 20$5.96
MA 50$4.88
MA 200$10.03
MACDBullish
VolumeDecreasing
Fear & Greed Index90.88
Valuation
Fair Value$30.15
GradeUndervalued
TypeValue
Risk Assessment
Beta1.79
Volatility112.66%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.